Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel
Clinical trial NCT02586025 · COMPLETED
Trial details
- NCT number
- NCT02586025
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-14
- Primary completion
- 2017-10-23
- Enrollment
- 329
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.